ECSP078014A - Regimen de dosificacion para prasugrel - Google Patents

Regimen de dosificacion para prasugrel

Info

Publication number
ECSP078014A
ECSP078014A EC2007008014A ECSP078014A ECSP078014A EC SP078014 A ECSP078014 A EC SP078014A EC 2007008014 A EC2007008014 A EC 2007008014A EC SP078014 A ECSP078014 A EC SP078014A EC SP078014 A ECSP078014 A EC SP078014A
Authority
EC
Ecuador
Prior art keywords
prasugrel
dosage regime
dosage
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
EC2007008014A
Other languages
English (en)
Inventor
John Thomas Brandt
Nagy Alphonse Farid
Joseph Anthony Jakubowski
Christopher David Payne
Govinda Jayanath Weerakkody
Kenneth John Winters
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP078014A publication Critical patent/ECSP078014A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un régimen de dosificación para tratar la enfermedad vascular en un humano, que comprende las etapas de administrar una dosificación de carga de alrededor de 30 mg hasta 70 mg de dosis de carga de prasugrel o una sal farmacéuticamente aceptable del mismo, y posteriormente administrar un régimen diario de dosificación de alrededor de 7.5 mg a 15 mg de dosis de mantenimiento de prasugrel o una sal farmacéuticamente aceptable del mismo.
EC2007008014A 2005-06-17 2007-12-14 Regimen de dosificacion para prasugrel ECSP078014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69174005P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
ECSP078014A true ECSP078014A (es) 2008-01-23

Family

ID=37571073

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007008014A ECSP078014A (es) 2005-06-17 2007-12-14 Regimen de dosificacion para prasugrel

Country Status (18)

Country Link
US (1) US20090156632A1 (es)
EP (1) EP1893205A4 (es)
JP (1) JP2008543853A (es)
KR (1) KR20080016647A (es)
CN (1) CN101198329A (es)
AU (1) AU2006259538A1 (es)
BR (1) BRPI0612624A2 (es)
CA (1) CA2612315A1 (es)
EA (1) EA200800075A1 (es)
EC (1) ECSP078014A (es)
GT (1) GT200600263A (es)
IL (1) IL187486A0 (es)
MA (1) MA29722B1 (es)
MX (1) MX2007015430A (es)
NO (1) NO20080244L (es)
TN (1) TNSN07474A1 (es)
WO (1) WO2006138317A2 (es)
ZA (1) ZA200710769B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101647842B1 (ko) * 2006-12-07 2016-08-11 다이이찌 산쿄 가부시키가이샤 저장 안정성이 개선된 의약 조성물
EP2100610A4 (en) 2006-12-07 2009-12-02 Daiichi Sankyo Co Ltd PHARMACEUTICAL COMPOSITION WITH LOW SUBSTITUTED HYDROXYPROPYL CELLULOSE
RU2470636C2 (ru) 2007-04-27 2012-12-27 Сайдекс Фамэсьютиклз, Инк. Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты)
ES2769949T3 (es) 2009-05-13 2020-06-29 Cydex Pharmaceuticals Inc Composiciones farmacéuticas que comprenden prasugrel y derivados de ciclodextrina y métodos de preparación y uso de las mismas
US10376532B2 (en) * 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
TR201006802A1 (tr) * 2010-08-17 2012-03-21 Sanovel İlaç San. Ve Ti̇c. A.Ş. Prasugrelin oral yolla dağılan formülasyonları.
EP2409685A3 (en) 2010-07-19 2012-02-01 Sanovel Ilac Sanayi ve Ticaret A.S. Orally-disintegrating formulations of prasugrel
WO2016203018A1 (en) 2015-06-19 2016-12-22 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions of prasugrel hydrobromide
WO2018167447A1 (en) * 2017-03-14 2018-09-20 University Of Sheffield Low dose aspirin (1-50 mg) together with antiplatelets such as ticagrelor of anticoagulants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US6544981B2 (en) * 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JP4001199B2 (ja) * 2000-07-06 2007-10-31 第一三共株式会社 ヒドロピリジン誘導体酸付加塩
KR20030014294A (ko) * 2000-07-06 2003-02-15 상꾜 가부시키가이샤 히드로피리딘 유도체 산부가염
PL206138B1 (pl) * 2000-12-25 2010-07-30 Daiichi Sankyo Company Limiteddaiichi Sankyo Company Limited Kompozycja farmaceutyczna zawierająca aspirynę oraz zestaw i zastosowanie składników kompozycji
JP4874482B2 (ja) * 2000-12-25 2012-02-15 第一三共株式会社 アスピリンを含有する医薬組成物
WO2004098713A2 (en) * 2003-05-05 2004-11-18 Eli Lilly And Company Treating cardiovascular diseases with a compound of formula (i) (cs 747 - prasugrel; rn 150322-43-4)

Also Published As

Publication number Publication date
EP1893205A4 (en) 2010-06-30
MA29722B1 (fr) 2008-09-01
TNSN07474A1 (en) 2009-03-17
EA200800075A1 (ru) 2008-04-28
NO20080244L (no) 2008-01-14
CA2612315A1 (en) 2006-12-28
JP2008543853A (ja) 2008-12-04
AU2006259538A1 (en) 2006-12-28
MX2007015430A (es) 2008-02-21
ZA200710769B (en) 2009-09-30
KR20080016647A (ko) 2008-02-21
WO2006138317A3 (en) 2007-05-03
WO2006138317A2 (en) 2006-12-28
EP1893205A2 (en) 2008-03-05
US20090156632A1 (en) 2009-06-18
GT200600263A (es) 2007-02-23
IL187486A0 (en) 2008-06-05
BRPI0612624A2 (pt) 2016-11-29
CN101198329A (zh) 2008-06-11

Similar Documents

Publication Publication Date Title
ECSP078014A (es) Regimen de dosificacion para prasugrel
AR050418A1 (es) Dosificacion fija de anticuerpos her
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
AR090885A1 (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
CR11724A (es) Agente para tratar enfermedades
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
MX2016010179A (es) Composiciones de donepezilo y métodos para tratar la enfermedad de alzheimer.
NO20055880L (no) Memantin orale doseringsformer
AR082803A1 (es) Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
AR105184A1 (es) Comprimidos de liberación inmediata que contienen un fármaco y procesos para formar los comprimidos
CL2024003601A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
AR058194A1 (es) Medicamentos que comprenden un agente antimuscarinico y un corticoesteroide
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
JP2017531042A5 (es)
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno
ES2572180T3 (es) Formulaciones de liberación controlada que comprenden unidad(es) discreta(s) sin recubrimiento y una matriz de liberación prolongada
CR9572A (es) Regimen de dosificacion para prasugrel
ATE298240T1 (de) Getrennte dosis therapien mit gefässschädigender aktivität
AR045074A1 (es) Uso de cd164 soluble en desordenes inflamatorios y autoinmunes